Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Proof-of-Concept Study of Brimonidine Eye Drops for the Treatment of Dry Eye Disease (DED)

Trial Profile

A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Proof-of-Concept Study of Brimonidine Eye Drops for the Treatment of Dry Eye Disease (DED)

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs Brimonidine (Primary) ; Loteprednol etabonate (Primary)
  • Indications Dry eyes
  • Focus Adverse reactions; Proof of concept
  • Sponsors Ocugen
  • Most Recent Events

    • 23 Oct 2018 According to an Ocugen media release, data from the trial will be presented at the 2018 Annual Meeting of The American Academy of Ophthalmology (AAO).
    • 09 Jul 2018 Status changed from recruiting to completed.
    • 20 Mar 2018 According to an Ocugen media release, this study met its primary endpoint of tolerability over a 12-week period.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top